Microbiota Modulation: A New Pillar in aGVHD Treatment 

Microbiota Modulation: A New Pillar in aGVHD Treatment 

Professor Mohamad Mohty, Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University, Paris, discusses a paradigm shift in managing acute graft-versus-host disease (aGVHD).He highlights the critical role of gut microbiota dysbiosis in the pathogenesis of aGVHD following allogeneic hematopoietic stem cell transplantation and elaborates on the therapeutic potential of microbiota modulation. 
ASH China Voice丨Zunmin Zhu / Mingfeng Zhao / Wenyi Lu: IL-18 and RQR8 Suicide-Switch Dual-Armored CLL-1 CAR-T Cells Enhance the Efficacy and Safety of AML Therapy 

ASH China Voice丨Zunmin Zhu / Mingfeng Zhao / Wenyi Lu: IL-18 and RQR8 Suicide-Switch Dual-Armored CLL-1 CAR-T Cells Enhance the Efficacy and Safety of AML Therapy 

The 67th American Society of Hematology (ASH) Annual Meeting will be held from December 6 to 9, 2025, in Orlando, USA. As one of the largest, most influential, and most comprehensive international congresses in hematology, ASH attracts tens of thousands of experts and scholars from around the world each year to share the latest advances and breakthrough research in the field.
2025 FACO | Professors Tetsuya Mitsudomi & Yun Gyoo Lee: Strengthening China–Japan–Korea Collaboration to Address Shared Challenges in Lung Cancer Care

2025 FACO | Professors Tetsuya Mitsudomi & Yun Gyoo Lee: Strengthening China–Japan–Korea Collaboration to Address Shared Challenges in Lung Cancer Care

China, Japan, and South Korea have long ranked among the countries with the highest incidence of lung cancer worldwide. With a heavy disease burden, urgent unmet medical needs, and remarkably similar disease characteristics, strengthening trilateral collaboration among these East Asian nations is critical to advancing clinical oncology and addressing shared challenges in lung cancer management.